2011
DOI: 10.1590/s1677-55382011000200003
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: The combined use of radiation therapy (RT) and androgen deprivation for patients with localized high-risk prostate cancer is commonly accepted as the standard treatment among uro-oncologists. Preclinical studies have provided rationale for the use of this combination. Additionally, results of phase 3 studies using conventional doses of RT have supported the combined approach. Other phase 3 studies have also shown a benefit for using higher doses of RT; however, the role of androgen deprivation in this context … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
7
0

Year Published

2012
2012
2018
2018

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 15 publications
(7 citation statements)
references
References 76 publications
0
7
0
Order By: Relevance
“…PCa is a double-stage disease, which usually starts as a treatable and poorly aggressive neoplasm. Early PCa can be treated by a combination of surgery, radiation and hormonal therapy [2]. The last option includes castration and pharmacological disruption of androgen-receptor (AR) signalling, which is a major proliferation stimulus for prostate cells.…”
Section: Introduction: Prostate Cancer Epigeneticsmentioning
confidence: 99%
“…PCa is a double-stage disease, which usually starts as a treatable and poorly aggressive neoplasm. Early PCa can be treated by a combination of surgery, radiation and hormonal therapy [2]. The last option includes castration and pharmacological disruption of androgen-receptor (AR) signalling, which is a major proliferation stimulus for prostate cells.…”
Section: Introduction: Prostate Cancer Epigeneticsmentioning
confidence: 99%
“…In the 1990s, ADT such as luteinizing hormone-releasing hormone (LH-RH) agonist or antiandrogens were tested as a combined modality therapy with RT ( 67 ). Phase III studies showed that ADT combined with RT allowed for better tumor control and survival as compared to RT alone in intermediate- and high-risk patients, and it is now considered as a standard treatment ( 68 70 ). However, despite ADT–RT combined treatments, long-term follow-up at 10 years shows that about 50% of patients relapse and eventually 10–25% die of PCa ( 68 , 71 , 72 ), which further strengthens the need for novel drugs especially in the high-risk category.…”
Section: Combining Molecular Targeting and Rt In Pcamentioning
confidence: 99%
“…Several well‐conducted randomized trials, recently reviewed elsewhere, show that EBRT combined with neoadjuvant and adjuvant ADT is superior to EBRT alone. The converse is also true; men with high‐risk localized prostate cancer have improved local control and survival when EBRT is added to ADT compared with ADT monotherapy .…”
Section: What Is the Optimal Treatment For Men With High‐risk Localizmentioning
confidence: 99%